COULD IT BE BEHÇET'S DISEASE? PHYSICIANS IN PRIMARY HEALTHCARE ARE THE FIRST TO RESPOND
Abstract
Keywords
Full Text:
PDFReferences
Leccese P, Alpsoy E. Behçet's Disease: An Overview of Etiopathogenesis. Front Immunol 2019; 10:1067.
Bulur I, Onder M. Behçet disease: New aspects. Clinics in Dermatology 2017; 35(5):421–34.
Alpsoy E, Bozca BC, Bilgic A. Behçet Disease: An Update for Dermatologists. Am J Clin Dermatol 2021; 22(4):477-502.
Nakamura J, Meguro A, Ishii G, Mihara T, et al. The association analysis between HLA-A*26 and Behçet's disease. Sci Rep 2019; 9(1):4426.
Vural, S, Boyvat, A. The skin in Behçet's disease: Mucocutaneous findings and differential diagnosis. JEADV Clin Pract 2022; 1:11– 20.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1-11.
Davatchi F, Assaad-Khalil S, Calamia KT, et al; International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28(3):338-47.
Cho SB, Zheng Z, Ahn KJ, et al. Serum IgA reactivity against GroEL of Streptococcus sanguinis and human heterogeneous nuclear ribonucleoprotein A2/B1 in patients with Behçet disease. Br J Dermatol 2013; 168(5):977-83.
Takeuchi M, Karasawa Y, Harimoto K, et al. Analysis of Th Cell-related Cytokine Production in Behçet Disease Patients with Uveitis Before and After Infliximab Treatment. Ocul Immunol Inflamm 2017; 25(1): 52-61.
Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Ther Adv Chronic Dis 2014; 5:112-34.
Mat C, Yurdakul S, Sevim A, Özyazgan Y, Tüzün Y. Behçet's syndrome: facts and controversies. Clin Dermatol 2013; 31:352-61.
Ilhan B, Can M, Alibaz-Oner F, Yilmaz-Oner S, Polat-Korkmaz O, Ozen G, Mumcu G, Maradit Kremers H, Direskeneli H. Fatigue in patients with Behçet's syndrome: relationship with quality of life, depression, anxiety, disability and disease activity. Int J Rheum Dis 2018; 21(12):2139-45.
Alpsoy E. New Evidence-Based Treatment Approach in Behçet's Disease. Patholog Res Int 2012: 871019.
Bozca BC, Alpsoy E. Experimental Therapeutic Solutions for Behcet's Disease. J Exp Pharmacol 2021; 13:127-45.
Shahneh ZF, Mohammadian M, Babaloo Z, Baradaran B. New approaches in immunotherapy of behçet disease. Adv Pharm Bull 2013; 3:9-11.
Hatemi G, Yazici Y, Yazici H. Behçet’s syndrome. Rheum Dis Clin North Am 2013; 39:245-61.
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 2018; 77:808-18.
DOI: https://doi.org/10.22190/FUMB221205001K
Refbacks
- There are currently no refbacks.
© University of Niš, Serbia
Creative Commons licence CC BY-NC-ND
ISSN 0354-4699 (Print)
ISSN 2406-050X (Online)